| Krina Bhimjibhai Viroliya, MD | |
|
404 Fountain St, Albert Lea, MN 56007-2406 | |
| (507) 373-2384 | |
| Not Available |
| Full Name | Krina Bhimjibhai Viroliya |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Location | 404 Fountain St, Albert Lea, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396373676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RA0000X | Internal Medicine - Adolescent Medicine | 74298 (Minnesota) | Secondary |
| 208M00000X | Hospitalist | 74298 (Minnesota) | Primary |
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Ridgeview Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528364429 PECOS PAC ID: 9234041997 Enrollment ID: O20031111000183 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Minnesota Valley Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730248907 PECOS PAC ID: 9032006507 Enrollment ID: O20040301000309 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Sibley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740240225 PECOS PAC ID: 3870722499 Enrollment ID: O20140418000315 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Krina Bhimjibhai Viroliya, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Krina Bhimjibhai Viroliya, MD 404 Fountain St, Albert Lea, MN 56007-2406 Ph: (507) 373-2384 |
News Archive
Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.
A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.
BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Researchers in the United States and Canada have described the potential for a transgenic mouse model to serve as an effective platform for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease course in humans.
› Verified 1 days ago